PART 04 : Introduction
• Key market highlights
• Pipeline analysis PART 05 : Market landscape
• Market overview
• Market size and forecast
• Five forces analysis PART 06 : Regulatory approval
• Orphan drug legislation PART 07 : Market segmentation by product type
• Biologics
• Non-biologics PART 08 : Geographical segmentation
• Orphan drugs market in Americas
• Orphan drugs market in EMEA
• Orphan Drugs Market in APAC PART 09 : Decision framework PART 10 : Drivers and challenges
• Market Drivers
• Impact of drivers on key customer segments
• Market Challenges
• Impact of challenges on key customer segments PART 11 : Market trends
• Emerging applications for orphan drug development
• Increasing focus on development of biologics
• Repurposing of non-orphan drugs to orphan drugs PART 12 : Competitive Scenario
• Vendor landscape PART 13 : Key vendor analysis
• AbbVie
• Celgene
• F . Hoffmann La Roche
• Novartis
• Other prominent vendors PART 14 : Appendix
• List of Abbreviations List of Exhibits Exhibit 01 : Overview of phase III molecules for few vendors Exhibit 02 : Pipeline overview based on different therapies Exhibit 03 : Pipeline analysis Exhibit 04 : Global orphan drugs market snapshot Exhibit 05 : Orphan drug requests ' year-over-year growth 2014-2016 Exhibit 06 : Few breakthroughs in global orphan drugs market 2014-2016 Exhibit 07 : Global orphan drugs market 2016-2021 ($ billions ) Exhibit 08 : Opportunity analysis in global orphan drugs market Exhibit 09 : Five forces analysis Exhibit 10 : Global orphan drugs market segmentation based on product type Exhibit 11 : Increasing trend of approval of biologics Exhibit 12 : Global orphan drugs market for biologics 2016-2021 ($ billions ) Exhibit 13 : Few significant non-biologics approved as orphan drugs